Occlusion operation diagnosis and treatment system for intractable epilepsy and high shunt flow PFO patient
Through the blocking surgery diagnosis and treatment system for patients with refractory epilepsy with high-score flow PFO, electronic medical record data and effectiveness evaluation models are used to evaluate the effectiveness of patients undergoing PFO blocking surgery, and solve the lack of specific patient types in the prior art The evaluation questions improve the accuracy of surgical selection and management.
Patent Information
- Application Number
- PCT/CN2023/102662
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-04
- Filing Date
- 2023-06-27
- Publication Date
- 2024-11-07
AI Technical Summary
The prior art When judging whether patients with refractory epilepsy are suitable for undergoing foramen oval pupil surgery, there is a lack of effectiveness assessment for specific patient types. It is usually based only on the anatomical structure of the foramen oval, and it is impossible to accurately predict the effectiveness of the surgery. sex.
Provide a sealing surgical diagnosis and treatment system for patients with refractory epilepsy with high-score flow PFO, including patient medical record information acquisition and storage module, patient selection module, preoperative effectiveness evaluation module and postoperative management module, and analyze through electronic medical record data , evaluate the effectiveness of patients undergoing PFO closure surgery, combine clinical basic information and epilepsy history data, and use the effectiveness evaluation model to predict.
This system breaks through the inherent cognition that only relies on anatomical structures, provides new objective references and decision-making ideas for patients with refractory epilepsy, helps doctors to more accurately select suitable patients and perform postoperative management, and improves the effectiveness of the surgery and the quality of life of patients.
Smart Images

Figure CN2023102662_07112024_PF_FP_ABST
Abstract
Description
Diagnostic and treatment system for closure surgery of patients with refractory epilepsy and high-flow PFO
[0001] Priority application
[0002] This application claims priority to Chinese invention patent application CN2023104865029, "Occlusion surgical diagnosis and treatment system for patients with refractory epilepsy and high-flow PFO," filed on May 4, 2023, which is incorporated by reference in its entirety. Technical Field
[0003] The present invention relates to the field of epilepsy, and in particular to a closure surgery diagnosis and treatment system for patients with intractable epilepsy and high-flow PFO. Background Art
[0004] The foramen ovale is a passageway that directly connects the two atria during fetal development. Under normal physiological conditions, it typically closes anatomically within one year of age. If it remains closed after three years of age, it is called a patent foramen ovale (PFO). PFO is reportedly the most common congenital heart anomaly in adults, with an incidence of approximately 25%. A PFO is a potential channel for right-to-left shunt (RLS) when right atrial pressure exceeds left atrial pressure (e.g., pulmonary hypertension, coughing, sneezing, straining during defecation, or laughing). A PFO allows microemboli, air and inflammatory mediators, small molecules such as cholinergic compounds and glutamine, and some deoxygenated venous blood to bypass pulmonary metabolism and enter the systemic circulation directly, leading to cerebral endothelial dysfunction or altered cortical excitability, potentially causing stroke, migraine, and obstructive sleep apnea (OSA). In recent years, percutaneous PFO closure has become one of the most common and simplest catheter-based interventional procedures in adult cardiology.
[0005] Drug-refractory epilepsy (or drug-resistant epilepsy, abbreviated as refractory epilepsy) generally refers to a type of epilepsy that has been treated with at least two or more anti-epileptic drugs and has not responded well to regular treatment for more than two years. Patients with refractory epilepsy account for approximately 40% of all epilepsy patients. Although patients with refractory epilepsy only account for a small proportion of all epilepsy patients, frequent and severe epileptic seizures seriously damage the patient's physical health, resulting in a poor quality of life for the patient and a significantly increased mortality rate. At the same time, refractory epilepsy also brings a heavy economic burden to families and society. According to statistics from the World Health Organization, although only about 40% of epilepsy cases are refractory, refractory epilepsy accounts for 80% of the overall economic burden of epilepsy patients.
[0006] A population-based case-control study in the UK reported a 2.4% prevalence of epilepsy during long-term follow-up of patients with congenital heart disease, compared to a 0.62% prevalence in the general population. Another study showed that 4–18% of newborns with congenital heart disease experienced epileptic seizures during the perioperative period, suggesting that epilepsy may be associated with worse neurodevelopmental impairment in children with congenital heart disease, often presenting as intractable epilepsy. Of note, PFO patients often do not undergo surgical treatment during infancy due to their mild clinical symptoms, and the long-term impact of PFO on epilepsy may be overlooked.
[0007] Although Chinese patent CN113040835A discloses that PFO closure surgery can effectively control epileptic seizures in epileptic patients with PFO, the existing technology often recommends PFO closure surgery for PFO patients based on their PFO anatomy assessment, and lacks effectiveness assessment for specific patient types (e.g., patients with refractory epilepsy).
[0008] Summary of the Invention
[0009] In a first aspect, the present invention provides a system for occlusion surgery and treatment of patients with intractable epilepsy and high-flow PFO, characterized in that the system comprises:
[0010] a patient medical record information acquisition and storage module, configured to acquire and store electronic medical record data of epilepsy patients, wherein the types of electronic medical record data include basic clinical data, epileptic seizure history data, and PFO examination data; the basic clinical data include gender and age at surgery; the epileptic seizure history data include age at onset of epilepsy, frequency of epileptic seizures, whether 24-hour EEG examination is normal, and duration of epileptic seizures; the PFO examination data include whether PFO exists and right-to-left shunt grade; the electronic medical record data include sample data from a sample population and subject data from subjects;
[0011] a patient selection module, the patient selection module acquiring the subject data through the patient medical record information acquisition and storage module, and selecting the subject who may be suitable for PFO closure surgery based on the subject data;
[0012] a preoperative effectiveness evaluation module, configured to perform a preoperative effectiveness evaluation of the PFO closure surgery on the subject selected by the patient selection module; the preoperative effectiveness evaluation module comprising an evaluation submodule, the evaluation submodule acquiring the subject data through the patient medical record information acquisition and storage module, and invoking an effectiveness evaluation model to analyze the subject data to evaluate the effectiveness of the subject undergoing the PFO closure surgery, wherein the effectiveness is calculated by the following formula: S = β1×X1+β2×X2+β3×X3+β4×X4+β5×X5+β6×X6;
[0013] Among them, β1, β2, …, β6 represent the weights of characteristic variables; S represents the comprehensive effectiveness score, X1 represents the surgical age classification, X2 represents the epilepsy onset age classification, X3 represents gender, X4 represents the epilepsy seizure frequency classification, X5 represents whether the 24-hour EEG examination is normal or not, and X6 represents the epilepsy seizure duration classification; β1 to β6 represent the proportion of the OR values of X1 to X6 to the sum of the OR values of the characteristic variables.
[0014] In some embodiments, the system further includes a postoperative management module for tracking the postoperative health status of the subject undergoing the PFO closure surgery; the postoperative management module includes a health guidance submodule, and the health guidance submodule is used to provide reminder information to the subject undergoing the PFO closure surgery, and the reminder information includes medication reminders, health reminders and examination reminders.
[0015] In some embodiments, the postoperative management module further includes a postoperative tracking submodule, which is used to receive and analyze the subject's postoperative efficacy data, wherein the postoperative efficacy data includes epileptic seizure data, daily medication data, and occlusion device data.
[0016] In some embodiments, the drugs include antiplatelet drugs and anti-epileptic drugs; the occlusion device data include the location and function of the occlusion device, the presence or absence of occlusion device thrombosis, the presence or absence of cardiac structural abnormalities and residual shunts after surgery; the epileptic seizure data include the frequency and duration of epileptic seizures.
[0017] In some embodiments, the post-operative efficacy data is from the subject and / or a supervisor.
[0018] In some embodiments, the patient selection module further comprises:
[0019] Inclusion criteria were used to identify epilepsy patients who may be suitable for the PFO closure surgery, including: (1) age of surgery was 9-55 years old, (2) epilepsy patients with PFO;
[0020] Exclusion criteria are used to exclude patients who are not suitable for the PFO closure surgery. The exclusion criteria include: (1) patients who do not meet the inclusion criteria; (2) patients with secondary epilepsy, where the causative factors of secondary epilepsy include one or more of tumors, brain trauma, encephalitis, and neurotoxicity; and (3) patients who are intolerant to antiplatelet therapy drugs.
[0021] In some embodiments, the preoperative effectiveness assessment module further includes a model building submodule, and the model building submodule performs statistical analysis on the sample data to determine the effectiveness assessment model.
[0022] In some embodiments, the subject data and the postoperative efficacy data of the subject can be used as new sample data to optimize the effectiveness evaluation model.
[0023] In some embodiments, the basic clinical data also includes: one or more of: height, weight, BMI, diastolic blood pressure, systolic blood pressure, blood sugar index, blood routine examination index, smoking history, drinking history, physical activity scale evaluation, dietary nutrition scale evaluation, mental health scale evaluation, and previous history of chronic diseases.
[0024] In some embodiments, the epileptic seizure history data also includes one or more of family history of epilepsy, type of epileptic seizure, aura manifestations, motor epilepsy manifestations, characteristic manifestations of epileptic seizures, standard anti-epileptic medication course, number of types of anti-epileptic drugs taken, history of anti-epileptic drug use, severity of epileptic seizures, whether accompanied by migraines, and whether the MRI examination is normal.
[0025] In some embodiments, the PFO examination data further includes whether there is occluder thrombosis and the relationship between the PFO and surrounding tissues.
[0026] In some embodiments, the effectiveness assessment model scores the subject, and the subject with a comprehensive score exceeding 40, 50, 60, 70, 80 or 90 points is assessed as having an estimated effectiveness of the PFO closure surgery.
[0027] In some embodiments, the subject whose composite score is greater than 60 is assessed as having a predicted success rate of the PFO closure surgery.
[0028] In some embodiments, the system further includes a surgical procedure standardization management module.
[0029] In a second aspect, the present invention further provides a method for constructing an effectiveness evaluation model, wherein the effectiveness evaluation model is used to evaluate the effectiveness of PFO closure surgery in patients with refractory epilepsy and high-flow PFO, characterized in that the method comprises:
[0030] S1 obtains sample data from a sample population, where the sample data includes clinical basic data, epileptic seizure history data, and PFO examination data;
[0031] S2 performs statistical analysis on the sample data and screens out predictive variables, wherein the screened predictive variables include gender, age at surgery, age at onset of epilepsy, frequency of epileptic seizures, 24-hour EEG examination results, and duration of epileptic seizures;
[0032] S3 establishes the effectiveness evaluation model based on the screened predictor variables.
[0033] In some embodiments, the statistical analysis method comprises a two-stage analysis strategy and bootstrap method. Beneficial effects
[0034] In the prior art, determining whether a patient is suitable for PFO closure surgery is often based solely on the anatomical structure of the patient's foramen ovale. In other words, for certain types of patients (such as those with intractable epilepsy associated with PFO, as targeted by the present invention), the prior art still relies solely on the anatomical structure of the foramen ovale, and even fails to determine their suitability for PFO closure surgery.
[0035] The present invention provides a closure surgery diagnosis and treatment system for patients with refractory epilepsy and high-flow PFO. The patient selection module of the diagnosis and treatment system provided by the present invention can make a preliminary selection of epilepsy patients based on hard conditions. The effectiveness evaluation model in the effectiveness evaluation module only requires the basic clinical information of the epilepsy patient (age and gender of surgery) and basic epilepsy history data (age of epilepsy onset, frequency of epileptic seizures, 24-hour EEG examination results and duration of epileptic seizures) to evaluate the subjects selected by the patient selection module (which can also be understood as soft conditions), which helps epilepsy patients and doctors to predict and visualize in advance the effectiveness of patent foramen ovale closure surgery for patients with refractory epilepsy. The diagnosis and treatment system provided by the present invention is based on the electronic medical record data of epilepsy patients, breaking through the inherent cognition in the prior art that only relies on the anatomical structure of the foramen ovale to decide whether to accept patent foramen ovale closure surgery, and provides a new objective reference and decision-making idea for whether refractory epilepsy patients accept patent foramen ovale closure surgery, and also helps to assist clinical evaluation.
[0036] The postoperative management module of the diagnosis and treatment system provided by the present invention will also conduct long-term postoperative tracking of patients with intractable epilepsy who undergo patent foramen ovale closure surgery to obtain their postoperative efficacy data, wherein the postoperative efficacy data can come from the subject himself and the supervisor (such as medical staff in the hospital). By comparing the postoperative efficacy data from the subject himself with the postoperative efficacy data from the supervisor, the compliance of the subject can be further evaluated, and to a certain extent, the problem of the subject concealing the actual medication and epileptic seizures can be avoided. The postoperative efficacy data of the subject (such as the subject with a higher comprehensive score and who undergoes closure surgery, the subject with a lower comprehensive score and who undergoes closure surgery) and their corresponding electronic medical record data can be used as new sample data to further optimize the effectiveness evaluation model of the present invention. In addition, the new sample data will also be fed back to the patient selection module to further clarify the inclusion criteria and exclusion criteria.
[0037] In summary, the patient inclusion and exclusion evaluation system of the diagnosis and treatment system provided by the present invention is complete and standardized, which helps to guide the selection, decision-making and postoperative management of epilepsy patients suitable for PFO closure surgery. BRIEF DESCRIPTION OF THE DRAWINGS
[0038] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following is a brief introduction to the drawings required for the embodiments or the description of the prior art. In all drawings, similar elements or parts are generally identified by similar reference numerals. In the drawings, the various elements or parts are not necessarily drawn according to the actual scale. Obviously, the drawings described below are some embodiments of the present invention. For those of ordinary skill in the art, other drawings can also be obtained based on these drawings without inventive work.
[0039] FIG1 is a schematic diagram of a validity evaluation model according to a first embodiment of the present invention;
[0040] FIG2 is a schematic diagram of the architecture of a diagnosis and treatment system according to a second embodiment of the present invention;
[0041] FIG3 is a schematic diagram of a module of a diagnosis and treatment system according to a second embodiment of the present invention;
[0042] FIG4 is a schematic diagram of a module of a diagnosis and treatment system according to a second embodiment of the present invention;
[0043] FIG5 is a schematic diagram of a module of a diagnosis and treatment system according to a second embodiment of the present invention;
[0044] FIG6 is a summary diagram of information related to 14 clinical indicators screened out in Example 1 of the present invention;
[0045] FIG. 7 shows the OR value information of the characteristic variables of the effectiveness evaluation model according to the first embodiment of the present invention.
[0046] Summary of the reference numerals: 100 is a diagnosis and treatment system, 102 is a patient medical record information acquisition and storage module, 104 is a patient selection module, 106 is a preoperative effectiveness evaluation module, 108 is a postoperative management module, 110 is a surgical process standardization management module, 202 is an evaluation submodule, 204 is a model building submodule, 206 is a postoperative tracking submodule, 208 is a health guidance submodule, 302 is a first terminal, 304 is a second terminal, and 306 is a network. DETAILED DESCRIPTION
[0047] To make the purpose, technical solutions, and advantages of the embodiments of the present invention more clear, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts are within the scope of protection of the present invention.
[0048] Herein, suffixes such as "module," "component," or "unit" used to represent elements are only used to facilitate description of the present invention and have no specific meaning. Therefore, "module," "component," or "unit" may be used interchangeably.
[0049] As used herein, terms such as "upper," "lower," "inner," "outer," "front," "back," "one end," and "the other end" indicate positions or locations based on those shown in the accompanying drawings. These terms are intended solely to facilitate and simplify the description of the present invention and are not intended to indicate or imply that the devices or components referred to must have, be constructed, or operate in a specific orientation. Therefore, they should not be construed as limitations on the present invention. Furthermore, the terms "first" and "second" are used for descriptive purposes only and should not be construed as indicating or implying relative importance.
[0050] As used herein, "and / or" includes any and all combinations of one or more of the associated listed items.
[0051] Herein, "plurality" means two or more than two, ie, it includes two, three, four, five, etc.
[0052] It should be noted that, in this document, the terms "comprises," "includes," or any other variations thereof are intended to encompass non-exclusive inclusion, such that a process, method, article, or apparatus comprising a series of elements includes not only those elements but also other elements not explicitly listed, or elements inherent to such process, method, article, or apparatus. In the absence of further limitations, an element defined by the phrase "comprising a ..." does not exclude the presence of other identical elements in the process, method, article, or apparatus comprising the element.
[0053] As used in this specification, the term "about" typically means + / - 5% of the stated value, more typically + / - 4% of the stated value, more typically + / - 3% of the stated value, more typically + / - 2% of the stated value, even more typically + / - 1% of the stated value, and even more typically + / - 0.5% of the stated value.
[0054] In this specification, certain embodiments may be disclosed in a format that is within a certain range. It should be understood that such descriptions of "being within a certain range" are merely for convenience and brevity and should not be interpreted as a rigid limitation on the disclosed range. Therefore, the description of a range should be considered to have specifically disclosed all possible sub-ranges and independent numerical values within this range. For example, the description of a range of 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as individual numbers within this range, such as 1, 2, 3, 4, 5, and 6. Regardless of the breadth of the range, the above rules apply.
[0055] Example 1
[0056] This study is based on data from 33 patients with intractable epilepsy and grade 2-3 right-to-left shunt (RLS) who underwent PFO closure surgery and were followed up for one year. The clinical characteristics of these patients were analyzed, and a PFO closure effectiveness evaluation model for epilepsy patients (especially those with intractable epilepsy) was established.
[0057] Transthoracic echocardiography (TTE) was used to assess the presence of a PFO and the grade of RLS. A contrast agent containing microbubble pellets was mixed with a stirred solution of 8 mL of saline, 1 mL of blood, and 1 mL of air and injected into the antecubital vein to increase sensitivity. RLS was assessed at rest, during the Valsalva procedure, and during coughing. A PFO was considered present if two or more microbubbles were present in the left atrium or left ventricle within three cardiac cycles after maximal right atrial opacification. In a semiquantitative analysis, the degree of RLS was assessed by TTE and quantified by the number of microbubbles (microemboli) detected per frame in the left atrium: grade 0 = no microbubble signal (no RLS); grade 1 = 1 to 20 (1 to 10 unilateral) microbubble signals (mild RLS); grade 2 = >20 (>10 unilateral) microbubble signals, non-curtain pattern (moderate RLS); and grade 3 = curtain or shower pattern of microbubbles (massive RLS). In the present invention, “high flow rate” means an RLS level of 2 or 3.
[0058] Next, this example adopts a two-stage analysis strategy. In the initial stage, the clinical information and prognostic outcomes of the above-mentioned patients with refractory epilepsy (i.e., the significantly improved group ("operatively effective") and the group without significant improvement ("operatively ineffective")) are classified and compared. The primary outcome is the percentage decrease in the average number of epileptic seizures within one year of follow-up after PFO closure surgery compared with the average number of epileptic seizures within one year before surgery. A percentage decrease of more than 30% is considered a significant improvement ("operatively effective"). This example screened out 14 clinical indicators to enter the variable verification model. The 14 clinical indicators include gender, RLS grade, age at surgery, age at onset of epilepsy, course of epilepsy, aura manifestations (aura classification), standard anti-epileptic medication course, frequency of epilepsy attacks within one year before surgery, duration of epileptic seizures within one year before surgery, number of types of anti-epileptic drugs taken, severity of epileptic seizures (whether there are other serious symptoms), whether accompanied by migraine, whether the 24-hour EEG examination is normal, and whether the MRI examination is normal (Figure 6).
[0059] During the validation phase, this example employed a bootstrap method. After 200 sampling validations and with a test level of 0.1, the percentage of significant models (defined in this context as the proportion of models where a particular feature variable remained significant after 200 sampling validation analyses) was calculated. A validity threshold exceeding 15% was used to establish a PFO closure surgery effectiveness assessment model. It should be noted that the effectiveness prediction model provided by this invention can be analyzed in conjunction with newly acquired sample data for further enrichment and optimization.
[0060] The characteristic variables of the PFO closure surgery effectiveness evaluation model in this embodiment include age at surgery, age at epilepsy onset, gender, frequency of epilepsy seizures within the year before surgery, duration of epilepsy seizures within the year before surgery, and whether the 24-hour EEG examination is normal (Figure 7). The OR represents the odds ratio (OR) of these characteristic variables; the OR value is a statistic that quantifies the strength of the association between two events, representing the ratio of the probability of the outcome occurring after an exposure (in this case, the characteristic variable being tested, the same below) to the probability of the outcome occurring in the absence of the same exposure.
[0061] The PFO closure surgery effectiveness evaluation model can score the effectiveness of the PFO closure surgery on the subject before the PFO closure surgery is performed. In some embodiments, the PFO closure surgery effectiveness evaluation model is: S = β1×X1+β2×X2+β3×X3+β4×X4+β5×X5+β6×X6
[0062] Among them, β1, β2, …, β6 represent the weights of characteristic variables; S represents the comprehensive effectiveness score, X1 represents the age classification of surgery, X2 represents the age classification of epilepsy onset, X3 represents gender, X4 represents the average frequency classification of epileptic seizures within one year before surgery, X5 represents whether the 24-hour EEG examination is normal or not, and X6 represents the average duration classification of epileptic seizures within one year before surgery.
[0063] In some embodiments, the weight of the feature variable is the ratio of the OR value of the feature variable to the sum of the OR values of the feature variables. Specifically, β1 represents the ratio of the OR value of X1 to the sum of the OR values of the feature variables, β2 represents the ratio of the OR value of X2 to the sum of the OR values of the feature variables, β3 represents the ratio of the OR value of X3 to the sum of the OR values of the feature variables, β4 represents the ratio of the OR value of X4 to the sum of the OR values of the feature variables, β5 represents the ratio of the OR value of X5 to the sum of the OR values of the feature variables, and β6 represents the ratio of the OR value of X6 to the sum of the OR values of the feature variables.
[0064] Specifically, the calculation formula for the weight of each feature variable is: OR total = OR1 + OR2 + OR3 + OR4 + OR5 + OR6.
[0065] In some embodiments, a comprehensive score of the subject (with a full score of 100) can be calculated according to the following formula, wherein the comprehensive score indicates the effectiveness of the PFO closure surgery performed on the subject ( FIG. 1 ).
[0066] In some embodiments, the PFO closure surgery effectiveness evaluation model is: S = 15 × X1 + 19 × X2 + 14 × X3 + 11 × X4 + 15 × X5 + 7.5 × X6
[0067] Specifically, the value ranges of the above characteristic variables are as follows:
[0068] When the surgical age is >18 years old, the surgical age classification (X1) is 0; when the surgical age is ≤18 years old, the surgical age classification (X1) is 1.
[0069] When the age of epilepsy onset is >18 years old, the value of the age of epilepsy onset classification (X2) is 0; when the age of epilepsy onset is ≤18 years old, the value of the age of epilepsy onset classification (X2) is 1.
[0070] When the gender is female, the value of gender(X3) is 0; when the gender is male, the value of gender(X3) is 1.
[0071] When the average frequency of epileptic seizures in the year before surgery is greater than 1 time per week or day, the value of the average frequency grade of epileptic seizures in the year before surgery (X4) is 0; when the average frequency of epileptic seizures in the year before surgery is greater than 1 time per month, the value of the average frequency grade of epileptic seizures in the year before surgery (X4) is 1; when the average frequency of epileptic seizures in the year before surgery is ≤ 1 time per month, the value of the average frequency grade of epileptic seizures in the year before surgery (X4) is 2.
[0072] When the 24-hour EEG examination is abnormal, the value of 24-hour EEG examination normal or not (X5) is 0; when the 24-hour EEG examination is normal or not (X5) is 1.
[0073] When the average duration of epileptic seizures within the year before surgery is less than 1 minute per seizure, the value of the average duration of epileptic seizures graded within the year before surgery (X6) is 0; when the average duration of epileptic seizures within the year before surgery is ≤1-3 minutes per seizure, the value of the average duration of epileptic seizures graded within the year before surgery (X6) is 1; when the average duration of epileptic seizures within the year before surgery is greater than 3 minutes per seizure, the value of the average duration of epileptic seizures graded within the year before surgery (X6) is 2.
[0074] In some embodiments, a subject with a preoperative efficacy composite score greater than 40, 50, 60, 70, 80, or 90 points is assessed as having a good postoperative efficacy benefit after undergoing PFO closure surgery. In some embodiments, a subject with a preoperative efficacy composite score greater than 60 points is assessed as having a good postoperative efficacy benefit after undergoing PFO closure surgery.
[0075] Example 2
[0076] Based on the above-mentioned PFO closure surgery effectiveness evaluation model, combined with the electronic medical record data of epilepsy patients, the surgical process of PFO closure surgery, and postoperative management and follow-up data, the present invention provides a closure surgery diagnosis and treatment system for patients with refractory epilepsy and high-flow PFO.
[0077] See Figure 2, which is an optional architectural diagram of a closure surgery diagnosis and treatment system for patients with intractable epilepsy and high-flow PFO provided by an embodiment of the present invention. In order to support an exemplary application, the terminal (a first terminal 302 and a second terminal 304 are shown as an example) is connected to the diagnosis and treatment system via a network 306. The network involved in the present invention can be a wide area network or a local area network, or a combination of the two, using a wireless link to achieve data transmission. The terminal involved in the present invention can be various types of user terminals such as smart phones, tablet computers, and laptops. The terminal can be used to display an interface for inputting subject data and / or sample data, as well as an interface for displaying the evaluation results of the diagnosis and treatment system.
[0078] The following describes an exemplary structure of the diagnosis and treatment system of the present invention. In some embodiments, as shown in FIG3 , the diagnosis and treatment system 100 may include:
[0079] The patient medical record information acquisition and storage module 102 is used to acquire and store electronic medical record data of epilepsy patients. The types of electronic medical record data include clinical basic data, epileptic seizure history data and PFO examination data. The electronic medical record data includes sample data from a sample population and subject data from subjects.
[0080] In some embodiments, the clinical basic data include gender and age at surgery, the epilepsy seizure history data include age of epilepsy onset, frequency of epilepsy seizures, whether the 24-hour EEG examination is normal or not, and duration of epilepsy seizures, and the PFO examination data include whether PFO exists and the right-to-left shunt grade.
[0081] In some embodiments, the basic clinical data include gender, age at surgery, height, weight, BMI, diastolic blood pressure, systolic blood pressure, blood sugar index, blood routine test index, smoking history, drinking history, physical activity scale evaluation, diet nutrition scale evaluation, mental health scale evaluation (for example, including depression, anxiety, loneliness, sleep quality scale evaluation), previous chronic disease history (for example, including hypertension, diabetes, cognitive dysfunction, sleep disorder, history of brain trauma or other cranial nerve dysfunction diseases). In some embodiments, the epileptic seizure history data include family history of epilepsy, age of onset of epilepsy, type of epileptic seizure, aura manifestation, motor epilepsy manifestation, frequency of epilepsy within one year before surgery, duration of epileptic seizure within one year before surgery, characteristic manifestations of epileptic seizures, standard anti-epileptic medication course, number of anti-epileptic drug types, history of anti-epileptic drug use, severity of epileptic seizures, whether accompanied by migraine, whether 24-hour EEG examination is normal, whether MRI examination is normal. In some embodiments, the PFO examination data include whether PFO exists, right-to-left shunt grade, presence or absence of thrombus, and the relationship between PFO and surrounding tissues.
[0082] The electronic medical record data can be transmitted to the patient medical record information acquisition and storage module 102 via the network 306 through the first terminal 302 and / or the second terminal 304. In some embodiments, the first terminal 302 can be a hospital end, and the second terminal 304 can be a patient end. In some embodiments, the basic clinical data can be obtained by the epilepsy patient's self-report and completion of corresponding scales (such as physical activity scale, dietary nutrition scale, mental health scale). In some embodiments, the epileptic seizure history data can be obtained by the epilepsy patient's self-report, completion of corresponding examinations (such as 24-hour EEG examination and MRI examination) and preoperative epilepsy log records. In some embodiments, the PFO examination data can be obtained by the epilepsy patient completing corresponding examinations (such as transthoracic right heart echocardiography, transesophageal echocardiography, pulmonary artery pressure assessment and PFO anatomical assessment).
[0083] The patient selection module 104 is configured to select the subject who may be suitable for PFO closure surgery based on the electronic medical record data (specifically, clinical basic data and PFO examination data).
[0084] In some embodiments, the patient selection module 104 further includes:
[0085] Inclusion criteria were used to identify epilepsy patients who may be suitable for the PFO closure surgery, including: (1) age of surgery was 9-55 years old, (2) epilepsy patients with PFO;
[0086] Exclusion criteria are used to exclude patients who are not suitable for the PFO closure surgery. The exclusion criteria include: (1) patients who do not meet the inclusion criteria; (2) patients with secondary epilepsy, where the causative factors of secondary epilepsy include one or more of tumors, brain trauma, encephalitis, and neurotoxicity; and (3) patients who are intolerant to antiplatelet therapy drugs.
[0087] The preoperative effectiveness evaluation module 106 is configured to perform a preoperative effectiveness evaluation of the PFO closure surgery on the subject selected by the patient selection module 104. The preoperative effectiveness evaluation module 106 includes an evaluation submodule 202. The evaluation submodule 202 obtains the subject data through the patient information acquisition and storage module 102 and uses an effectiveness evaluation model to analyze the subject data to evaluate the effectiveness of the PFO closure surgery for the subject.
[0088] In some embodiments, the characteristic variables of the effectiveness evaluation model include epileptic seizure duration, whether the 24-hour EEG examination is normal or not, epileptic seizure frequency, gender, onset age and surgical age.
[0089] In some embodiments, the effectiveness assessment model scores the subject, and the subject with a comprehensive score exceeding 40, 50, 60, 70, 80 or 90 points is assessed as having an estimated effectiveness of the PFO closure surgery.
[0090] In some embodiments, the subject with a comprehensive score greater than 60 is assessed as having a predicted success rate for the PFO closure surgery.
[0091] In some embodiments, the pre-operative effectiveness evaluation module 106 further includes a model building submodule 204 , and the model building submodule 204 performs statistical analysis on the sample data to determine the effectiveness evaluation model.
[0092] In some embodiments, as shown in FIG4 , the diagnosis and treatment system 100 may further include a postoperative management module 108 for tracking the postoperative health status of the subject who undergoes the PFO closure surgery.
[0093] In some embodiments, the postoperative management module 108 includes a health guidance submodule 208. The health guidance submodule 208 is used to provide reminder information to the subject undergoing the PFO closure surgery. In some embodiments, the reminder information includes medication reminders, health reminders, and check-up reminders. In some embodiments, the health reminders include regular exercise, healthy diet, and changing bad habits (such as quitting smoking and limiting alcohol). In some embodiments, the health reminders also include reminding the subject to stay at home for 1 month after undergoing the PFO closure surgery and avoid strenuous exercise and heavy lifting. In some embodiments, the drugs of the medication reminder include antiplatelet drugs and anti-epileptic drugs. In some specific embodiments, the medication regimen of the antiplatelet drug includes: 100 mg / day of aspirin combined with 75 mg / day of clopidogrel within 6 months after surgery; 100 mg / day of aspirin during the 7th to 12th month after surgery. In some embodiments, the medication regimen of the anti-epileptic drug is to maintain the subject's preoperative anti-epileptic drug treatment regimen. In some specific embodiments, the health guidance submodule 208 will provide the medication reminder at a specific frequency based on the subject's medication regimen, such as once a day, twice a day, etc. In some embodiments, the medication reminder time can also be preset, such as one or more medication time points (e.g., 9:00, 14:00, 20:00). In some embodiments, the examination reminder includes epilepsy-related examinations and PFO-related examinations. In some embodiments, the examination reminder time can be preset, such as every 3 months after surgery.
[0094] In some embodiments, the postoperative management module 108 further includes a postoperative tracking submodule 206. The postoperative tracking submodule 206 is used to receive and analyze the postoperative efficacy data of the subject. In some embodiments, the postoperative efficacy data include epileptic seizure data, daily medication data and occlusion device data. In some embodiments, the postoperative efficacy data comes from the subject. In some embodiments, the postoperative efficacy data comes from a supervisor, such as a medical staff. In some embodiments, the daily medication data includes antiplatelet therapeutic drugs and anti-epileptic drugs. In some embodiments, the daily medication data may also include other drugs. In some embodiments, the epileptic seizure data includes the frequency of epileptic seizures and the duration of epileptic seizures. In some embodiments, the occlusion device data includes the location and function of the occlusion device, the presence or absence of occlusion device thrombus, whether the heart structure is abnormal and residual shunt after surgery.
[0095] When a preset event occurs, the postoperative tracking submodule 206 provides feedback information to the subject and the supervisor. In some embodiments, the preset event may include one or more of the following: (1) abnormal daily medication data (e.g., the antiplatelet therapy drug and / or the anti-epileptic drug data were not received at the preset time point (e.g., 20:00) (i.e., missed medication), the subject took an inappropriate medication); (2) abnormal epileptic seizure data (e.g., increased epileptic seizure frequency and / or epileptic seizure duration (i.e., worsening epileptic seizures)); (3) abnormal occlusion device data (e.g., occlusion device thrombosis); (4) failure to receive postoperative efficacy data from the supervisor within a certain period (e.g., 2 weeks) after the occurrence of the above preset event or the preset inspection reminder time. In some embodiments, the feedback information may be fed back to the subject via a video message, an audio message, or other possible means. After receiving the feedback information, the subject should go to the hospital for treatment in a timely manner. After the treatment, the postoperative efficacy data of the subject from the supervisor will be transmitted to the postoperative tracking submodule 206. In some embodiments, the postoperative tracking submodule 206 may also be used to compare the postoperative efficacy data of the subject with the postoperative efficacy data from the supervisor to assess the subject's compliance with the current medication regimen.
[0096] In other embodiments, the feedback information may also be information encouraging the subject to maintain the current medication regimen.
[0097] As shown in FIG5 , in some embodiments, the postoperative tracking submodule 206 transmits the postoperative efficacy data to the model building submodule 204. The postoperative efficacy data and subject data of the subject can be used as newly acquired sample data (which can also be classified into a "significantly improved group" and a "no significant improvement group") to further optimize the effectiveness evaluation model.
[0098] In some embodiments, the postoperative tracking submodule 206 can also transmit the postoperative efficacy data to the patient selection module 104, and the patient selection module will further update the exclusion criteria and the inclusion criteria (for example, excluding a specific group of epilepsy patients who are not suitable for PFO surgery).
[0099] In some embodiments, the diagnosis and treatment system 100 may further include a standardized surgical procedure management module 110, which specifically includes:
[0100] Device insertion process S401: Under local anesthesia, puncture the femoral vein and insert a guidewire. Select the appropriate type of occlusion device according to the size of the foramen ovale. Insert the sheath along the guidewire under ultrasound guidance through the foramen ovale into the left atrium to release the patent foramen ovale occluder.
[0101] Positioning process S402: using transthoracic echocardiography to ensure that the occlusion device is correctly positioned at the foramen ovale.
[0102] The process of placing the occluding device S403: slowly releasing the occluding device (the occluding device is in the shape of a sieve, and tissue gradually fills the sieve holes in the later stage to close the foramen ovale) until it is completely filled and blocks the foramen ovale.
[0103] Inspection process S404: using transthoracic echocardiography again to ensure that the occlusion device has successfully occluded the foramen ovale.
[0104] Instrument removal process S405: After the operation, the catheter and instruments are slowly pulled out from the groin, and the femoral vein puncture point is compressed.
[0105] Perioperative observation process S406: The patient will be transferred to the recovery room and will be observed for 7 days to ensure that no complications occur.
[0106] The diagnosis and treatment system provided by the present invention has a complete patient inclusion and exclusion evaluation system and standardized management, which helps to guide the selection, decision-making and postoperative management of epilepsy patients suitable for PFO closure surgery.
[0107] A specific application scenario of the present invention is given below.
[0108] Patient A suffers from intractable epilepsy with a PFO. After being input through the first terminal 302, Patient A's electronic medical record data is transmitted via the network 306 to the patient medical record information acquisition and storage module 102 of the diagnosis and treatment system 100. The patient medical record information acquisition and storage module 102 acquires and stores Patient A's electronic medical record data. Based on pre-set inclusion and exclusion criteria, if Patient Selection Module 104 selects Patient A as a suitable candidate for PFO closure surgery, the preoperative effectiveness assessment module 106 (specifically, the assessment submodule 202) acquires Patient A's electronic medical record data and invokes an established effectiveness assessment model to analyze Patient A's electronic medical record data and assess the effectiveness of PFO closure surgery for Patient A. As output, the preoperative effectiveness assessment module 106 generates a report indicating the effectiveness of PFO closure surgery for Patient A and transmits the assessment results to the first terminal 302 and / or the second terminal 304 via the network 306. If Patient A's comprehensive score exceeds a pre-set effectiveness score threshold (e.g., 60 points), PFO closure surgery is recommended for Patient A. If patient A undergoes PFO closure surgery, the postoperative management module 108 will provide long-term guidance and tracking for patient A. Patient A will receive reminders from the health guidance submodule 208 and transmit the postoperative efficacy data to the postoperative tracking submodule 206 via the network 306 through the second terminal 304. Patient A should also visit the recommended or cooperating hospital regularly. The hospital will transmit the postoperative efficacy data of patient A from the supervisor to the postoperative tracking submodule 206 through the first terminal 302. The postoperative tracking submodule 206 will track and analyze the postoperative efficacy data to ensure that patient A's anti-epileptic drug regimen and closure device are normal. If patient A's epileptic seizure symptoms are severe after surgery and / or the closure device is abnormal, patient A will be reminded to go to the hospital for treatment. The hospital will closely evaluate patient A and adjust the treatment plan to control his epileptic seizures and / or keep the closure device normal. Patient A's data (subject data + postoperative efficacy data) can be used as new sample data to further optimize the effectiveness evaluation model of the evaluation submodule 202 and the exclusion and inclusion criteria of the patient selection module 104.
[0109] Through the description of the above embodiments, those skilled in the art can clearly understand that the above-mentioned embodiment methods can be implemented by means of software plus the necessary general hardware platform, and of course can also be implemented by hardware, but in many cases the former is a better embodiment. Based on this understanding, the technical solution of the present invention is essentially or the part that contributes to the prior art can be embodied in the form of a software product, which is stored in a storage medium (such as ROM / RAM, magnetic disk, optical disk), including a number of instructions for enabling a computer terminal (which can be a mobile phone, computer, server, or network device, etc.) to execute the methods described in each embodiment of the present invention.
[0110] The embodiments of the present invention are described above in conjunction with the accompanying drawings, but the present invention is not limited to the above-mentioned specific implementation methods. The above-mentioned specific implementation methods are merely illustrative and not restrictive. Under the guidance of the present invention, ordinary technicians in this field can also make many forms without departing from the scope of protection of the present invention and the claims, all of which are protected by the present invention.
[0111] References
[0112] PTHagen,DGScholz,WDEdwards.Incidence and size of patent foramen ovale during the first 10 decades of life:an autopsy study of 965 normal hearts.MAYO CLIN PROC 1984;59(1):17-20.doi:10.1016 / s0025-6196(12)60336-x pmid:66944271984-01-01].
[0113] PACalvert, BSRana, ACKydd, LMShapiro. Patent foramen ovale: anatomy, outcomes, and closure. NAT REV CARDIOL 2011;8(3):148-60.doi:10.1038 / nrcardio.2010.224 pmid:212831482011-03-01].
[0114] SFrimoldi,S.Ott,E.Rexhaj,et al.Patent Foramen Ovale Closure in Obstructive Sleep Apnea Improves Blood Pressure and Cardiovascular Function.HYPERTENSION 2015;66(5):1050-57.doi:10.1161 / HYPERTENSIONAHA.115.06303pmid:26418025.[(c)2015American Heart Association, Inc.:*2015-11-01].
[0115] WG Rd Kussmaul.Different Strokes.ANN INTERN MED 2020;172(11):761-62.doi:10.7326 / M20-1879pmid:324220672020-06-02].
[0116] S.Kutty,P.P.Sengupta,B.K.Khandheria.Patent foramen ovale:the known and the to be known.J AM COLL CARDIOL 2012;59(19):1665-71.doi:10.1016 / j.jacc.2011.09.085pmid:22554596.[Copyright(c)2012American College of Cardiology Foundation.Published by Elsevier Inc.All rights reserved.:*2012-05-08].
[0117] K.I.Strauss,K.V.Elisevich.Brain region and epilepsy-associated differences in inflammatory mediator levels in medically refractory mesial temporal lobe epilepsy.J Neuroinflammation 2016;13(1):270.doi:10.1186 / s12974-016-0727-z pmid:277377162016-10-13].
[0118] J.Detour,C.Bund,C.Behr,et al.Metabolomic characterization of human hippocampus from drug-resistant epilepsy with mesial temporal seizure.EPILEPSIA 2018;59(3):607-16.doi:10.1111 / epi.14000 pmid:29341105.[Wiley Periodicals,Inc.(c)2018International League Against Epilepsy.:*2018-03-01].
[0119] M.Puligheddu,M.Melis,G.Pillolla,et al.Rationale for an adjunctive therapy with fenofibrate in pharmacoresistant nocturnal frontal lobe epilepsy.EPILEPSIA 2017;58(10):1762-70.doi:10.1111 / epi.13863 pmid:28766701.[Wiley Periodicals,Inc.(c)2017International League Against Epilepsy.:*2017-10-01].
[0120] M.Eickhoff,S.Kovac,P.Shahabi,et al.Spreading depression triggers ictaform activity in partially disinhibited neuronal tissues.EXP NEUROL 2014;253:1-15.doi:10.1016 / j.expneurol.2013.12.008 pmid:24368193.[Copyright(c)2013Elsevier Inc.All rights reserved.:*2014-03-01].
[0121] L.Zhang,X.Zhu,X.Qiu,et al.Relationship between right-to-left shunt and migraine in patients with epilepsy:a single-centre,cross-sectional study in China.BMJ OPEN 2018;8(10):e24144.doi:10.1136 / bmjopen-2018-024144pmid:30297353.[(c)Author(s)(or their employer(s))2018.Re-use permitted under CC BY-NC.No commercial re-use.See rights and permissions.Published by BMJ.:*2018-10-08].
[0122] Madhkour R,Wahl A,Praz F,Meier B.Amplatzer patent foramen ovale occluder:safety and efficacy.EXPERT REV MED DEVIC 2019;16(3):173-82.doi:10.1080 / 17434440.2019.1581060.
[0123] Billett J,Cowie MR,Gatzoulis MA,Vonder Muhll IF,Majeed A.Comorbidity,healthcare utilisation and process of care measures in patients with congenital heart disease in the UK:cross-sectional,population-based study with case-control analysis.Heart(British Cardiac Society)2008;94(9):1194-99.doi:10.1136 / hrt.2007.122671.
[0124] B.Desnous,M.Lenoir,A.Doussau,et al.Epilepsy and seizures in children with congenital heart disease:A prospective study.Seizure 2019;64:50-53.doi:10.1016 / j.seizure.2018.11.011 pmid:30557820.[Copyright(c)2018British Epilepsy Association.Published by Elsevier Ltd.All rights reserved.:*2019-01-01].
Claims
1. A closure surgery diagnosis and treatment system for patients with refractory epilepsy and high-flow PFO, characterized in that: The system comprises: A patient medical record information acquisition and storage module, used to acquire and store electronic medical record data of epilepsy patients, wherein the types of the electronic medical record data include basic clinical data, epilepsy attack history data and PFO examination data, wherein the basic clinical data include gender and age at surgery, the epilepsy attack history data include age at onset of epilepsy, frequency of epilepsy attacks, whether 24-hour EEG examination is normal or not and duration of epilepsy attacks, and the PFO examination data include whether PFO exists or not and right-to-left shunt grade; the electronic medical record data include sample data from a sample population and subject data from a subject; A patient selection module, wherein the patient selection module obtains the subject data through the patient medical record information acquisition and storage module, and selects the subject who may be suitable for PFO closure surgery based on the subject data; A preoperative effectiveness evaluation module is used to perform a preoperative effectiveness evaluation of the PFO closure surgery on the subject selected by the patient selection module; the preoperative effectiveness evaluation module includes an evaluation submodule, the evaluation submodule obtains the subject data through the patient medical record information acquisition and storage module, and calls the effectiveness evaluation model to analyze the subject data to evaluate the effectiveness of the subject receiving the PFO closure surgery; wherein the effectiveness is calculated by the following formula: S=β1×X1+β2×X2+β3×X3+β4×X4+β5×X5+β6×X6; Among them, β1, β2, …, β6 represent the weights of characteristic variables; S represents the comprehensive effectiveness score, X1 represents the surgical age classification, X2 represents the epilepsy onset age classification, X3 represents gender, X4 represents the epilepsy attack frequency classification, X5 represents whether the 24-hour EEG examination is normal or not, and X6 represents the epilepsy attack duration classification; β1 to β6 represent the proportion of the OR values of X1 to X6 to the sum of the OR values of the characteristic variables.
2. The system according to claim 1, characterized in that The system further includes a postoperative management module for tracking the postoperative health status of the subject undergoing the PFO closure surgery; the postoperative management module includes a health guidance submodule, and the health guidance submodule is used to provide reminder information to the subject undergoing the PFO closure surgery, and the reminder information includes medication reminders, health reminders and examination reminders.
3. The system according to claim 2, characterized in that The postoperative management module also includes a postoperative tracking submodule, which is used to receive and analyze the postoperative efficacy data of the subject, wherein the postoperative efficacy data includes epileptic seizure data, daily medication data and occlusion device data.
4. The system according to claim 3, characterized in that The drugs include antiplatelet drugs and anti-epileptic drugs; the occlusion device data include the location and function of the occlusion device, the presence or absence of occlusion device thrombus, the presence or absence of cardiac structural abnormalities and residual shunt after surgery; the epilepsy attack data include the frequency of epilepsy attacks and the duration of epilepsy attacks.
5. The system according to claim 3, characterized in that The postoperative efficacy data comes from the subject and / or the supervisor.
6. The system according to claim 1, wherein: The patient selection module further comprises: Inclusion criteria were used to identify epilepsy patients who might be suitable for the PFO closure surgery, and the inclusion criteria included: (1) patients aged 9-55 years at the time of surgery, (2) patients with epilepsy and PFO; Exclusion criteria are used to exclude patients who are not suitable for the PFO closure surgery. The exclusion criteria include: (1) patients who do not meet the inclusion criteria; (2) patients with secondary epilepsy, where the causative factors of secondary epilepsy include one or more of tumors, brain trauma, encephalitis, and neurotoxicity; and (3) patients who are intolerant to antiplatelet therapy drugs.
7. The system according to claim 1, characterized in that The preoperative effectiveness evaluation module also includes a model building submodule, and the model building submodule performs statistical analysis on the sample data to determine the effectiveness evaluation model.
8. The system according to claim 3, characterized in that The subject data and the postoperative efficacy data of the subject can be used as new sample data to optimize the effectiveness evaluation model.
9. The system according to claim 1, characterized in that The effectiveness evaluation model scores the subject, and the subject whose comprehensive score exceeds 40, 50, 60, 70, 80 or 90 points is evaluated as having an estimated effective rate of the PFO closure surgery.
10. The system according to claim 9, characterized in that The subjects whose comprehensive scores are greater than 60 points are evaluated as having an estimated effective PFO closure surgery.
Citation Information
Patent Citations
Modeling method for screening surgical patients
CN106264510A
Treatment plan intelligent generating system, method thereof, readable storage medium and electronic equipment
CN109754886A
Clinical intelligent assistant decision-making method and system for femoral neck fracture
CN110289095A
Plugging operation diagnosis and treatment system for refractory epilepsy patient with high-shunt-volume PFO
CN116230243A
Determining patient candidacy for epilepsy neurosurgical procedure
US11357444B1
